Eton Pharmaceuticals (ETON) Debt to Equity (2020 - 2025)
Eton Pharmaceuticals (ETON) has disclosed Debt to Equity for 6 consecutive years, with $1.17 as the latest value for Q4 2025.
- Quarterly Debt to Equity fell 4.26% to $1.17 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.17 through Dec 2025, down 4.26% year-over-year, with the annual reading at $1.17 for FY2025, 4.26% down from the prior year.
- Debt to Equity hit $1.17 in Q4 2025 for Eton Pharmaceuticals, down from $1.31 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.31 in Q3 2025 to a low of $0.02 in Q1 2021.
- Historically, Debt to Equity has averaged $0.38 across 5 years, with a median of $0.11 in 2023.
- Biggest five-year swings in Debt to Equity: decreased 23.9% in 2022 and later soared 408.72% in 2025.
- Year by year, Debt to Equity stood at $0.08 in 2021, then dropped by 1.79% to $0.08 in 2022, then soared by 340.08% to $0.35 in 2023, then surged by 251.07% to $1.22 in 2024, then dropped by 4.26% to $1.17 in 2025.
- Business Quant data shows Debt to Equity for ETON at $1.17 in Q4 2025, $1.31 in Q3 2025, and $1.26 in Q2 2025.